Biosimilars’ Generic-style Labeling Limits Data Promotion, Companies Say
Executive Summary
Given dearth of biosimilar-specific data on label for Sandoz’s filgrastim-sndz, biosimilar sponsors say they need way to discuss their products’ analytical and clinical data with health care providers and payers, while physicians want more data about the biosimilar itself in labeling.